Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases

NCT06342713 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT06342713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06342713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2024
Completion date
June 2, 2026
Enrollment
203 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, autoimmune diseases, healthy adult participants, healthy participants, healthy subjects, healthy volunteers, prurigo nodularis